Clinical Trial Update: Abequolixron (RGX-104) and Durvalumab in Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Abequolixron (RGX-104) in combination with Durvalumab for non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abequolixron (RGX-104)
• Durvalumab (durvalumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED